Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AssigneeUniversity of Kansas
InventorsValentino Stella, Roger Rajewski
Life of this patent
Estimating the term…
Abstract
Sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water insoluble drugs for oral, intranasal, or parenteral administration are disclosed.
Claims45
A purified cyclodextrin derivative composition which comprises a cyclodextrin derivative of formula ##STR3## wherein:
- n is 4, 5 or 6;
- R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are each, independently, O.sup.- or a O--(C.sub.2-6 alkylene)--SO.sub.3.sup.- group, and at least one of R.sub.1 and R.sub.2 is, independently, said O--(C.sub.2-6 alkylene)--SO.sub.3.sup.- group;
- and
- S.sub.1, S.sub.2, S.sub.3, S.sub.4, S.sub.5, S.sub.6, S.sub.7, S.sub.8 and S.sub.9 are each, independently, a pharmaceutically acceptable cation, and wherein said composition shows an absence of underivatized cyclodextrin as measured by thin-layer chromatography.
A composition comprising a drug complexed to a cyclodextrin derivative of formula (2):
- ##STR4## wherein:
- n=4, 5 or 6;
- R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, and R.sub.9 are each at least one of R.sub.1 and R.sub.2 is, independently, said O--(C .sub.2-6 alkylene)--SO.sub.3.sup.- group;
- and
- S.sub.1 to S.sub.9 are each, independently, a pharmaceutically acceptable cation;
- wherein said composition contains not more than 5 wt. % of underivatized cyclodextrin.
A pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier and a clathrate complex comprising a drug complexed to a cyclodextrin derivative of formula (2):
- ##STR5## wherein:
- n=4, 5 or 6;
- R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are each independently O.sup.- or a O--(C.sub.2-6 alkylene)--SO.sub.3.sup.- group, and at least one of R.sub.1 and R.sub.2 is, independently, said O--(C.sub.2-6 alkylene)--SO.sub.3.sup.- group;
- and
- S.sub.1 to S.sub.9 are each, independently, a pharmaceutically acceptable cation;
- wherein said composition contains not more than 5 wt. % of underivatized cyclodextrin.
A delayed release pharmaceutical composition, comprising a drug complexed to a purified cyclodextrin derivative of formula (2):
- ##STR6## wherein:
- n=4, 5 or 6;
- R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are each independently O.sup.- or a O--(C.sub.2-6 alkylene)SO.sub.3.sup.- group, and at least one of R.sub.1 and R.sub.2 is, independently said O--(C.sub.2-6 alkylene)--SO.sub.3.sup.- group;
- and
- S.sub.1 to S.sub.9 are each, independently, a pharmaceutically acceptable cation.
Dependencies are inferred from the claim text.